There can be no innovative therapeutic products without an innovative technological platform
Oncodesign Precision Medicine (OPM) is the essence of the dream that led to the creation of Oncodesign SA in 1995. OPM is a biotechnology company specialising in precision medicine applied to the discovery of treatments for metastatic and resistant cancers. Thanks to the technologies available through Oncodesign Services (ODS) and OPM, we have access to technologies that allow us to select the best drug candidates, discover the most effective kinase inhibitors and theranostic tools, and select the most relevant therapeutic targets in oncology. OPM's innovative technologies include:
- OncoSNIPER (selection of therapeutic targets for the treatment of resistant and metastatic cancers).
- Nanocyclix® (design and selection of small chemical molecules specific to kinases).
- PROMETHE (design and selection of radiolabelled biological molecules for systemic radiotherapy).
In summary :
- A CEO behind the creation and development of Oncodesign SA, listed on Euronext Growth between 1995 and 2022 (€45 million in revenue), and its transformation into two independent companies: ODS and OPM.
- An experienced team that participated in the creation, development, and funding of the companies, the sale of ODS and demerger/listing of OPM.
- Strong technological assets, well-known technologies, and interesting stages of maturity.
- A first round of funding, covered by OPM Management and planned before the end of 2022, making it possible to achieve development stages that appeal to investors.
- A first round of funding, covered by OPM Management and planned before the end of 2022, making it possible to achieve development stages that appeal to investors.
- Good knowledge of the ecosystem, in terms of both technology and finances.